Physician profile
Priya Sharma
NPI 1285643783
$1,008.01
in general payments reported to CMS, 2019-2025
16 companies · $235 in 2025
The $235 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $32.08 · 2021: $159 · 2022: $125 · 2023: $69.56 · 2024: $250 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $208.57 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ucb, INC. | $123.52 | 2024 | Fintepla |
| Sanofi Pasteur INC. | $112.79 | 2019-2024 | |
| Kaleo, INC. | $105.96 | 2020-2022 | |
| Pfizer INC. | $99.69 | 2019-2023 | |
| Cranial Technologies, INC | $72.78 | 2020-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $52.59 | 2024-2025 | |
| Sobi, INC | $44.61 | 2019-2023 | |
| Alk-Abello, INC | $32.33 | 2025 | Neffy |
| Kyowa Kirin, INC. | $25.99 | 2025 | |
| Biofire Diagnostics, LLC | $25.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $25.00 | 2023 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $23.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.37 | 2021 | |
| Genentech USA, INC. | $18.77 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $14.57 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.